Abstract

Objective To offer new insight for bladder cancer therapy through researching the microRNA-143-3p/TBX3 axis. Methods Differentially expressed microRNAs in bladder cancer were provided by databases to find microRNA that may regulate TBX3. qRT-PCR was utilized to test levels of TBX3 mRNA and microRNA-143-3p. Their binding was verified with a dual-luciferase method. Malignant cell behaviors were examined by cell functional experiments. Levels of TBX3 protein and proteins pertinent to epithelial-mesenchymal transition (EMT) were tested by western blot. Results TBX3 was highly expressed in bladder cancer cells. MicroRNA-143-3p presented the most conspicuously negative correlation with TBX3, and they had binding sites. Cell functional experiments proved that TBX3 facilitated bladder cancer cell functions and EMT. MicroRNA-143-3p was demonstrated to downregulate TBX3 expression. Rescue assay further illuminated that microRNA-143-3p repressed bladder cancer cell functions and EMT through downregulating TBX3 expression. Conclusion These data all indicated that TBX3 was modulated by microRNA-143-3p and acted as a cancer promoter gene in bladder cancer progression via affecting tumor proliferation, migration, invasion, and EMT. Therefore, a microRNA-143-3p/TBX3 network might be an underlying target for bladder cancer.

Highlights

  • Bladder cancer is a prevalent malignancy in the urinary system [1]

  • TBX3 overexpression is relevant to many cancers, such as liver cancer, pancreatic cancer, ovarian cancer, and head and neck squamous cell carcinoma [26]

  • It was unveiled that TBX3 expression was higher in cancer cells than in normal cells at mRNA and protein levels (Figures 1(a) and 1(b))

Read more

Summary

Introduction

Bladder cancer is a prevalent malignancy in the urinary system [1]. Nonmuscle infiltrating bladder cancer comprises most of all bladder cancer cases (70%-80%) and shows a favorable prognosis [2]. Muscle infiltrating bladder cancer shows a terrible therapeutic effect, and the recurrence rate is high [3]. Bladder cancer patients’ median survival is rather short (10-55 months). A patient’s poor prognosis often results from distant metastasis and high recurrence [4, 5], while epithelial-mesenchymal transition (EMT) facilitates invasiveness and activity of bladder cancer cells [6, 7]. It is critical to define the functional mechanism in the early stage of metastasis, such as migration, invasion, and EMT

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.